Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000800102 | SCV000939802 | pathogenic | not provided | 2024-11-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg2032*) in the VPS13A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VPS13A are known to be pathogenic (PMID: 12404112, 21598378). This variant is present in population databases (rs764376151, gnomAD 0.007%). This premature translational stop signal has been observed in individual(s) with chorea-acanthocytosis (PMID: 12404112). ClinVar contains an entry for this variant (Variation ID: 645922). For these reasons, this variant has been classified as Pathogenic. |
Prevention |
RCV003392604 | SCV004120315 | pathogenic | VPS13A-related disorder | 2023-02-27 | criteria provided, single submitter | clinical testing | The VPS13A c.6094C>T variant is predicted to result in premature protein termination (p.Arg2032*). This variant was reported in a patient with chorea-acanthocytosis (Dobson-Stone et al. 2002. PubMed ID: 12404112). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/9-79947028-C-T). Nonsense variants in VPS13A are expected to be pathogenic. This variant is interpreted as pathogenic. |
Fulgent Genetics, |
RCV005047078 | SCV005682548 | likely pathogenic | Chorea-acanthocytosis | 2024-01-23 | criteria provided, single submitter | clinical testing |